<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669354</url>
  </required_header>
  <id_info>
    <org_study_id>1R15AT010035-01</org_study_id>
    <nct_id>NCT03669354</nct_id>
  </id_info>
  <brief_title>Spinal Manipulation Services vs. Prescription Drug Therapy for Long-term Care</brief_title>
  <official_title>Spinal Manipulation Services vs. Prescription Drug Therapy for Long-term Care of Aged Medicare Beneficiaries With Chronic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dartmouth College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern California University of Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our overall objective is to assess the value of Spinal Manipulation Services as compared to&#xD;
      Prescription Drug Therapy for long-term management of chronic Law back Pain (LBP). Our&#xD;
      central hypothesis is that among aged Medicare beneficiaries with chronic LBP, utilization of&#xD;
      SMS offers superior value (to both patient and payer) for long-term care as compared to PDT.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research Design&#xD;
&#xD;
      This description applies to project specific aim 2.&#xD;
&#xD;
      Overview of Design and Methods: FFS Medicare beneficiaries will be surveyed and compared by&#xD;
      cohort for differences in response. Subjects will be randomly sampled from each of the four&#xD;
      cohorts (A, B, A2B &amp; B2A) identified in SA1.&#xD;
&#xD;
      Survey Instrument and Question Formulation: A validated survey instrument will be used to&#xD;
      collect subjective patient data. The survey will include questionnaires intended to evaluate&#xD;
      1) self-reported QOL, 2) satisfaction with care, and 3) beliefs regarding back pain and its&#xD;
      treatment. For assessment of self-reported QOL a version of the SF12 (Ware '96) will be used&#xD;
      and modified to account for time lapse between treatment for LBP and administration of the&#xD;
      survey, and to elicit treatment-specific responses The SF -12 has been previously validated&#xD;
      for measuring QOL among elderly patients, (Jakobsson '07) and patients using prescription&#xD;
      drugs. (Naveiro-Rilo '14) For assessment of satisfaction with care a 0-10 numeric scale will&#xD;
      be used. For assessment of beliefs a modified version of the validated LBP Treatment Beliefs&#xD;
      Questionnaire will be used. (Dima '15). A pre- test of all the survey instruments will be&#xD;
      conducted by distributing a prototype to a sample of 100 Medicare beneficiaries seen for LBP&#xD;
      at the SCU Health Center in Whittier, CA. Responses to the survey pre-test will inform any&#xD;
      need to edit the questionnaire for comprehensibility and ease of use, thus helping to ensure&#xD;
      instrument face validity. For ease of comprehension by older subjects, the survey questions&#xD;
      will be printed in large font and will be carefully worded to be brief, unambiguous, and free&#xD;
      of bias.&#xD;
&#xD;
      Survey Methods: ResDAC will initiate contact with random samples of beneficiaries who meet&#xD;
      criteria for inclusion in the cohorts identified in SA1. The Beneficiary Contact Service has&#xD;
      reviewed the survey plan with the PIs and provided an official cost estimate for this&#xD;
      service, which is routinely provided by the BCS with strict attention to patient protection.&#xD;
      Initial contact will be in the form of a Beneficiary Notification Letter, signed by the CMS&#xD;
      Privacy Officer. The letter will alert beneficiaries to the opportunity to voluntarily&#xD;
      participate in a healthcare survey. Recipients will be informed that they may decline&#xD;
      participation via enclosed reply forms, and will be given phone numbers to call CMS personnel&#xD;
      for additional information. After three weeks, the Beneficiary Contact Service will supply&#xD;
      the investigators with contact information for eligible beneficiaries (those who did not&#xD;
      decline to participate). The survey will be commenced by mailing the printed survey, cover&#xD;
      letter with informed consent form based on NCCIH guidelines, and a postage-paid return&#xD;
      envelope with detailed information about the survey. Participants can contact study personnel&#xD;
      if they have any questions. Follow up by phone after every two weeks or as needed will be&#xD;
      used to increase the rate of response.&#xD;
&#xD;
      Outcomes Measurement and Statistical Analysis: Testing will be done for between-cohort&#xD;
      differences in self-reported QOL, satisfaction with care, and beliefs about treatments for&#xD;
      LBP. Survey responses between the four groups will be compared using Pearson chi-square tests&#xD;
      and ANOVA. Demographic characteristics [e.g. sex as a biological variable, and age - because&#xD;
      age-related cognitive decline can affect survey responses (Wolinsky '15)] will be controlled&#xD;
      using linear regression for continuous survey items, proportional odds logistic regression&#xD;
      for ordinal items and multinomial regression for categorical items. In the multivariable&#xD;
      regression models equivalence between the four groups will be evaluated using likelihood&#xD;
      ratio or Wald tests. Given the multiplicity of testing (e.g. multiple groups for multiple&#xD;
      items), type I error inflation will be considered through used of Bonferonni corrections or&#xD;
      approaches for false discovery rates. Parametric tests of numeric data can be used to yield&#xD;
      unbiased answers when analyzing Likert scale responses. (Norman '10)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 6, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Self-reported QOL - Physical Health</measure>
    <time_frame>Base line. The survey (outcome measure) will be administered at at day one.</time_frame>
    <description>Self-reported Quality of Life&#xD;
Scale range- There are 12 questions with scales of categorical values. Corresponding numeric values will be given to each category.&#xD;
Value range from &quot;0&quot; to &quot;100&quot;&#xD;
Higher scores reflecting better outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Satisfaction With Care</measure>
    <time_frame>Base line.The survey (outcome measure) will be administered at day one.</time_frame>
    <description>Satisfaction with the Care&#xD;
The survey measured satisfaction for both SMT and PDT on a scale from 0-10, &quot;0&quot; being very dissatisfied and &quot;10&quot; being very satisfied. The patients were also given an option to select 'not applicable' if they never experienced either PDT or SMT.&#xD;
Higher numerical values indicate more satisfaction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beliefs Regarding Back Pain and Its Treatment</measure>
    <time_frame>Base line.The survey (outcome measure) will be administered at at day one.</time_frame>
    <description>Beliefs about Treatments for Low Back Pain&#xD;
Scale range- Categorical values of Strongly disagree, Disagree, Undecided, Agree, Strongly agree (corresponding to numeric value 1, 2, 3, 4, and 5).&#xD;
For purposes of analysis, we combined the response options into the following three categories: &quot;Disagree&quot; (Strongly Disagree and Disagree), &quot;Agree&quot; (Strongly Agree and Agree), and &quot;Undecided&quot;(left as is).&#xD;
For interpreting the results for this scale, we reported only the number of people who agreed with the statements.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">195</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Cohort SMT</arm_group_label>
    <description>Initiation in 2013 of long-term management with SMT, and no OAT for 12 months after initiating SMT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort OAT</arm_group_label>
    <description>Initiation in 2013 of long-term management with OAT, and no SMT for 12 months after initiating OAT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort SMTX</arm_group_label>
    <description>Any occurrence of SMT for cLBP in 2013, followed by initiation in 2013 of long-term management with OAT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort OATX</arm_group_label>
    <description>Any occurrence of OAT for cLBP in 2013, followed by initiation in 2013 of long-term management with SMT</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The target demographic is 65-84 year old Medicare beneficiaries who were treated for at&#xD;
        least one episode of low back pain and were enrolled in Medicare Parts A, B, and D.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Subjects will include Medicare Fee for Service beneficiaries (male or female), aged 65-84&#xD;
        years, residing in the US, and enrolled under Medicare Parts A, B, and D who have&#xD;
        experienced an episode of chronic low back pain (defined as lasting three months or&#xD;
        longer).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with diagnosis of cancer will be excluded from the study population to avoid&#xD;
             confounding of the reason for use of prescription opioids. Subjects over the age of 85&#xD;
             will also be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>64 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Anupama Kizhakkeveettil, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southern California University of Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southern California University of Health Sciences</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 30, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <results_first_submitted>January 7, 2021</results_first_submitted>
  <results_first_submitted_qc>September 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2021</results_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southern California University of Health Sciences</investigator_affiliation>
    <investigator_full_name>Anupama KizhakkeVeettil</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Prescription Drugs</keyword>
  <keyword>Spinal Manipulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 2, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT03669354/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort SMT</title>
          <description>Initiation in 2013 of long-term management with SMT, and no OAT for 12 months after initiating SMT</description>
        </group>
        <group group_id="P2">
          <title>Cohort OAT</title>
          <description>Initiation in 2013 of long-term management with OAT, and no SMT for 12 months after initiating OAT</description>
        </group>
        <group group_id="P3">
          <title>SMTX</title>
          <description>Any occurrence of SMT for cLBP in 2013, followed by initiation in 2013 of long-term management with OAT</description>
        </group>
        <group group_id="P4">
          <title>OATX</title>
          <description>Any occurrence of OAT for cLBP in 2013, followed by initiation in 2013 of long-term management with SMT</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort SMT</title>
          <description>Initiation in 2013 of long-term management with SMT, and no OAT for 12 months after initiating SMT</description>
        </group>
        <group group_id="B2">
          <title>Cohort OAT</title>
          <description>Initiation in 2013 of long-term management with OAT, and no SMT for 12 months after initiating OAT</description>
        </group>
        <group group_id="B3">
          <title>Cohort SMTX</title>
          <description>Any occurrence of SMT for cLBP in 2013, followed by initiation in 2013 of long-term management with OAT</description>
        </group>
        <group group_id="B4">
          <title>Cohort OATX</title>
          <description>Any occurrence of OAT for cLBP in 2013, followed by initiation in 2013 of long-term management with SMT</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="47"/>
            <count group_id="B4" value="53"/>
            <count group_id="B5" value="195"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="47"/>
                    <count group_id="B4" value="53"/>
                    <count group_id="B5" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78" spread="3.6"/>
                    <measurement group_id="B2" value="78" spread="3.7"/>
                    <measurement group_id="B3" value="78" spread="3.6"/>
                    <measurement group_id="B4" value="77" spread="4.1"/>
                    <measurement group_id="B5" value="78" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Based on Medicare CMS data reporting guidelines, we are required by Data Use Agreement to suppress the data with small cell numbers ( DUA #).&#xD;
Here &quot; 0&quot;means data were not reported because cell numbers are suppressed by Medicare regulations</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="73"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="47"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>Measure Analysis Population Description: Zero = not reported. Cell numbers are suppressed in accordance with Medicare regulations.</description>
          <population>Based on Medicare CMS data reporting guidelines, we are required by Data Use Agreement to suppress the data with small cell numbers ( DUA #).&#xD;
Here Zero means data were not reported because cell numbers are suppressed by Medicare regulations.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="71"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="45"/>
                    <count group_id="B4" value="50"/>
                    <count group_id="B5" value="185"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="185"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Self-reported QOL - Physical Health</title>
        <description>Self-reported Quality of Life&#xD;
Scale range- There are 12 questions with scales of categorical values. Corresponding numeric values will be given to each category.&#xD;
Value range from &quot;0&quot; to &quot;100&quot;&#xD;
Higher scores reflecting better outcomes.</description>
        <time_frame>Base line. The survey (outcome measure) will be administered at at day one.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort SMT</title>
            <description>Initiation in 2013 of long-term management with SMT, and no OAT for 12 months after initiating SMT</description>
          </group>
          <group group_id="O2">
            <title>Cohort OAT</title>
            <description>Initiation in 2013 of long-term management with OAT, and no SMT for 12 months after initiating OAT</description>
          </group>
          <group group_id="O3">
            <title>Cohort SMTX</title>
            <description>Any occurrence of SMT for cLBP in 2013, followed by initiation in 2013 of long-term management with OAT</description>
          </group>
          <group group_id="O4">
            <title>Cohort OATX</title>
            <description>Any occurrence of OAT for cLBP in 2013, followed by initiation in 2013 of long-term management with SMT.</description>
          </group>
        </group_list>
        <measure>
          <title>Self-reported QOL - Physical Health</title>
          <description>Self-reported Quality of Life&#xD;
Scale range- There are 12 questions with scales of categorical values. Corresponding numeric values will be given to each category.&#xD;
Value range from &quot;0&quot; to &quot;100&quot;&#xD;
Higher scores reflecting better outcomes.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" spread="11.2"/>
                    <measurement group_id="O2" value="28.8" spread="9.2"/>
                    <measurement group_id="O3" value="31.8" spread="8.7"/>
                    <measurement group_id="O4" value="32.9" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Satisfaction With Care</title>
        <description>Satisfaction with the Care&#xD;
The survey measured satisfaction for both SMT and PDT on a scale from 0-10, &quot;0&quot; being very dissatisfied and &quot;10&quot; being very satisfied. The patients were also given an option to select 'not applicable' if they never experienced either PDT or SMT.&#xD;
Higher numerical values indicate more satisfaction.</description>
        <time_frame>Base line.The survey (outcome measure) will be administered at day one.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cohort SMT</title>
            <description>Initiation in 2013 of long-term management with SMT, and no OAT for 12 months after initiating SMT</description>
          </group>
          <group group_id="O2">
            <title>Cohort OAT</title>
            <description>Initiation in 2013 of long-term management with OAT, and no SMT for 12 months after initiating OAT</description>
          </group>
          <group group_id="O3">
            <title>Cohort SMTX</title>
            <description>Any occurrence of SMT for cLBP in 2013, followed by initiation in 2013 of long-term management with OAT</description>
          </group>
          <group group_id="O4">
            <title>Cohort OATX</title>
            <description>Any occurrence of OAT for cLBP in 2013, followed by initiation in 2013 of long-term management with SMT</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction With Care</title>
          <description>Satisfaction with the Care&#xD;
The survey measured satisfaction for both SMT and PDT on a scale from 0-10, &quot;0&quot; being very dissatisfied and &quot;10&quot; being very satisfied. The patients were also given an option to select 'not applicable' if they never experienced either PDT or SMT.&#xD;
Higher numerical values indicate more satisfaction.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="1.7"/>
                    <measurement group_id="O2" value="7.2" spread="2.5"/>
                    <measurement group_id="O3" value="4.9" spread="3.33"/>
                    <measurement group_id="O4" value="8.2" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Beliefs Regarding Back Pain and Its Treatment</title>
        <description>Beliefs about Treatments for Low Back Pain&#xD;
Scale range- Categorical values of Strongly disagree, Disagree, Undecided, Agree, Strongly agree (corresponding to numeric value 1, 2, 3, 4, and 5).&#xD;
For purposes of analysis, we combined the response options into the following three categories: &quot;Disagree&quot; (Strongly Disagree and Disagree), &quot;Agree&quot; (Strongly Agree and Agree), and &quot;Undecided&quot;(left as is).&#xD;
For interpreting the results for this scale, we reported only the number of people who agreed with the statements.</description>
        <time_frame>Base line.The survey (outcome measure) will be administered at at day one.</time_frame>
        <population>Not every participant responded to all the questions. Results account for missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort SMT</title>
            <description>Initiation in 2013 of long-term management with SMT, and no OAT for 12 months after initiating SMT</description>
          </group>
          <group group_id="O2">
            <title>Cohort OAT</title>
            <description>Initiation in 2013 of long-term management with OAT, and no SMT for 12 months after initiating OAT</description>
          </group>
          <group group_id="O3">
            <title>Cohort SMTX</title>
            <description>Any occurrence of SMT for cLBP in 2013, followed by initiation in 2013 of long-term management with OAT</description>
          </group>
          <group group_id="O4">
            <title>Cohort OATX</title>
            <description>Any occurrence of OAT for cLBP in 2013, followed by initiation in 2013 of long-term management with SMT.</description>
          </group>
        </group_list>
        <measure>
          <title>Beliefs Regarding Back Pain and Its Treatment</title>
          <description>Beliefs about Treatments for Low Back Pain&#xD;
Scale range- Categorical values of Strongly disagree, Disagree, Undecided, Agree, Strongly agree (corresponding to numeric value 1, 2, 3, 4, and 5).&#xD;
For purposes of analysis, we combined the response options into the following three categories: &quot;Disagree&quot; (Strongly Disagree and Disagree), &quot;Agree&quot; (Strongly Agree and Agree), and &quot;Undecided&quot;(left as is).&#xD;
For interpreting the results for this scale, we reported only the number of people who agreed with the statements.</description>
          <population>Not every participant responded to all the questions. Results account for missing data.</population>
          <units>participants number</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Taking/having spinal manipulation for low back pain makes a lot of sense</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taking/having prescription drugs for low back pain makes a lot of sense</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I think spinal manipulation is pretty useless for people with low back pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I think taking prescription drugs are pretty useless for people with low back pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I have concerns about taking/having spinal manipulation for my low back pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I have concerns about taking/having prescription drugs for my low back pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I am confident spinal manipulation would be suitable treatment for my low back pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>I am confident prescription drugs would be suitable treatment for my low back pain.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>&quot;Adverse Events were not monitored/assessed&quot;</time_frame>
      <desc>&quot;Adverse Events were not monitored/assessed&quot;</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort SMT</title>
          <description>Initiation in 2013 of long-term management with SMT, and no OAT for 12 months after initiating SMT</description>
        </group>
        <group group_id="E2">
          <title>Cohort OAT</title>
          <description>Initiation in 2013 of long-term management with OAT, and no SMT for 12 months after initiating OAT</description>
        </group>
        <group group_id="E3">
          <title>Cohort SMTX</title>
          <description>Any occurrence of SMT for cLBP in 2013, followed by initiation in 2013 of long-term management with OAT</description>
        </group>
        <group group_id="E4">
          <title>Cohort OATX</title>
          <description>Any occurrence of OAT for cLBP in 2013, followed by initiation in 2013 of long-term management with SMT.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The overall response rate was lower than expected and we observed an age difference between respondents and non-respondents. In addition, recall bias is a potential limitation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Anupama Kizhakkeveettil</name_or_title>
      <organization>Southern California University Of Health Sciences</organization>
      <phone>(562) 475-5158</phone>
      <email>anu@scuhs.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

